A Johns Hopkins alternative-splicing platform, a second-time founder back from a successful exit, and the first company to travel the full length of the Blackbird Laboratories model — from nonprofit research grant to seed round to Blackbird BioHub bench space.
Every new accelerator model gets judged on the same question: can it actually produce companies? Three years in, Blackbird Laboratories just answered it.
Aletira Therapeutics is launching out of the Blackbird Laboratories and Johns Hopkins University partnership as the first company fully incubated and spun out of the Blackbird–Hopkins nest — a Baltimore gene therapy startup developing a new class of cell-type-specific genetic medicines based on alternative RNA splicing technology licensed from Hopkins.
Geoffrey M. Lynn, MD, PhD, will serve as Aletira’s founding CEO. Hugh Wells, who previously worked with Lynn at Avidea Technologies, joins as Chief Scientific Officer. The company has closed a seed financing round and taken residency inside the newly opened Blackbird BioHub at City Garage — the 35,000-square-foot incubator space whose launch BioBuzz covered in March.
For the Baltimore life sciences ecosystem, Aletira is more than another company announcement. It is the first clean end-to-end test of the operating model Blackbird has been building since Ravens owner Steve Bisciotti’s family office seeded the organization with a $100 million founding grant in late 2023. If the model works at scale, it rewrites the conversation about Baltimore’s place on the national biotech map.
The Full-Stack Proof Point Blackbird Was Built To Produce
Blackbird was designed from day one as a dual-armed platform. The nonprofit Blackbird Laboratories makes grants into translational research and commercialization activities at partner institutions — Johns Hopkins University, the University of Maryland Baltimore, and the Lieber Institute for Brain Development — to de-risk promising academic IP. The for-profit Blackbird BioVentures then participates as an early investor when those programs are ready to spin out. In the words of Blackbird CEO Matt Tremblay at the BioHub opening last month, roughly half of the $70 million Blackbird has deployed in its first three years has gone to research grants and collaborative projects, with the remainder invested across the portfolio.
That flywheel — non-dilutive catalytic capital in, venture equity on top, operational support throughout — is genuinely novel for Baltimore. The question has always been whether the full loop would actually close. Plenty of accelerators can write grants. Plenty of funds can cut seed checks. Very few can do both in integrated fashion on the same asset and then put it on a bench in a building they own.
Aletira closes that loop. The science originated in the lab of Jonathan Ling at Johns Hopkins, where researchers developed a splicing-based method for controlling when and where a therapeutic gene is expressed in the body — work published in Nature Communications and built on a growing patent portfolio around splicing-dependent gene regulation. Blackbird’s nonprofit arm funded the translational work needed to mature the platform into a commercial thesis. Blackbird’s venture arm participated in the seed round. And Blackbird’s real estate — the BioHub — provided the physical home for the company to spin up operations.
Tremblay has said Blackbird has backed 18 companies to date, with roughly 75% of them located in Baltimore and about 95% in Maryland, alongside 20 exploratory research projects that have produced four licensed programs so far. Aletira is the first of those four to make the full transition from grant-funded research project to venture-backed operating company housed inside Blackbird’s own walls.
“We’re excited to be starting from a position of strength — with a recently completed seed round, new facilities at the Blackbird BioHub, and the support of an extraordinary network across Blackbird and Hopkins.”
— Geoffrey M. Lynn, MD, PhD, Founding CEO, Aletira Therapeutics
Aletira’s Next-Gen Gene Therapy Approach
The scientific thesis behind Aletira is that the next meaningful frontier in gene therapy is not just getting DNA into cells — it is controlling which cells actually express the therapeutic payload once it arrives. Off-target expression in the wrong tissues is one of the primary sources of toxicity, immunogenicity, and dose-limiting side effects in the field today, and it is a central reason why many otherwise promising gene therapy programs stall in development.
The Hopkins technology Aletira is built on attacks that problem at the RNA level. By leveraging cell-type-specific alternative splicing — the natural process cells use to produce different protein variants in different tissues — the platform can essentially condition whether a delivered gene gets translated into a functional protein based on the splicing machinery present in that particular cell. In published proof-of-concept work, the underlying approach produced on-target expression in the intended cell type roughly half the time, compared with about 5% for the minipromoter systems that have historically been the field’s workhorse for cell-type targeting. That is not an incremental improvement; it is a step change.
If the platform translates, it has implications well beyond any single indication. A splicing-based expression layer could sit underneath AAV and non-viral delivery systems for retinal disease, CNS disorders, rare metabolic conditions, and a growing list of genetic indications where cell-type precision has been the missing piece. That breadth is exactly what makes the technology a platform bet rather than a single-asset bet — and it is why Aletira is being positioned as the first company out of the Blackbird–Hopkins pipeline rather than a one-off spinout.
Lynn framed the ambition in a launch statement: “I’m honored to serve as founding CEO and to be joining such an exceptional team as we leverage alternative splicing to build a new class of gene therapies. We believe this approach has the potential to meaningfully expand what’s possible in gene therapy.” More information on the company is available at aletiratherapeutics.com.
A Second-Time Founder With Venture-Caliber Pedigree
If the scientific story is the what, Geoff Lynn is a meaningful part of the why. Aletira is not Lynn’s first company. He founded and led Avidea Technologies, which was incubated in Baltimore at Johns Hopkins FastForward and built the SNAPvax T cell immunotherapy platform. Avidea’s platform stood on more than two decades of pioneering work by its world-class scientific founders and advisors from the National Institutes of Health’s Vaccine Research Center, the University of Oxford, and the Institute of Macromolecular Chemistry in Prague — a genuinely transatlantic scientific lineage that Lynn was able to assemble around a Baltimore-based operating company.
Avidea was acquired by Vaccitech — now Barinthus Biotherapeutics — in late 2021 in a $40 million transaction, with Lynn going on to serve as Chief Scientific Officer at Barinthus before supporting that company’s merger with Clywedog Therapeutics. He then joined Blackbird Labs as an Entrepreneur in Residence before stepping into the Aletira CEO role.
That arc — transatlantic scientific founding team, Baltimore-incubated company, strategic exit, senior role at the acquirer, EIR at the next-generation Baltimore platform, founding CEO again — is precisely the founder trajectory Baltimore has historically lost. In previous cycles, the Geoff Lynns of the ecosystem often ended up in Cambridge, South San Francisco, or Research Triangle Park by the time they were ready to run their second company. Keeping that flight path anchored in Baltimore is, by itself, a meaningful unlock for the region.
The bench of talent assembling around Lynn tells the same story. Hugh Wells, who previously worked with Lynn at Avidea, is stepping in as CSO — an early but important signal that Baltimore is beginning to produce something it has historically lacked: a cadre of second-time biotech operators with prior exits, raising capital and launching new companies locally. Virginia Burger, a Carnegie Mellon-trained computational biologist, is serving as CTO and building out the AI and computational infrastructure that underpins the platform’s ability to identify cell-type-specific splicing signatures. Jonathan Ling and colleagues at Hopkins, along with Johns Hopkins Technology Ventures, continue to shape the underlying science as it moves into the company.
Founder density is notoriously hard to manufacture. It either compounds or it doesn’t. The Aletira team — a repeat CEO, a repeat senior scientist from that same prior company, a specialist CTO, and continued academic collaboration with a world-class research group three miles from the company’s new bench space — is the kind of configuration that tends to attract the next wave of talent rather than repel it.
| The Blackbird Operating Model, In Practice A single company, four integrated Blackbird touchpoints: Research grant: Blackbird Laboratories (nonprofit) funded the translational work to mature Hopkins alternative splicing IP toward commercialization. Company creation: Blackbird served as an Entrepreneur-in-Residence home for Geoff Lynn between Barinthus and Aletira, shaping the business model and recruiting strategy. Seed capital: Blackbird BioVentures participated as an early investor in Aletira’s seed round without leading, consistent with its stated co-investment posture. Physical infrastructure: The company operates out of the newly opened Blackbird BioHub at City Garage, alongside shared labs, a vivarium run by Myologica, and neighboring tenants including EPOCH Epigenetics. |
Why This Matters for Baltimore’s Biotech Thesis
BioBuzz’s recent coverage of the Blackbird BioHub launch described the City Garage facility as a place where ideas, companies, and collaborators can physically come together. Aletira is the first company through the door that was also incubated by the organization that owns the door — and that distinction matters.
Baltimore has never had a shortage of world-class science. Johns Hopkins and the University of Maryland Baltimore are consistently among the top NIH-funded institutions in the country. What the region has historically lacked is the connective tissue between that research and the venture-backed companies that translate it — dedicated translational capital, operator-level talent that sticks around, and purpose-built physical infrastructure for early-stage biotech. Every biotech hub that has crossed the chasm from “great universities” to “great ecosystem” has solved those three problems simultaneously, not sequentially.
The Blackbird model is an explicit attempt to build all three at once. The nonprofit grant-making arm creates translational capital. The EIR program and the venture arm convert academic founders into operators and write the early checks. The BioHub, alongside complementary infrastructure like the 4MLK building at the UMB BioPark, Connect Labs by Wexford, and the UM-BILD Accelerator, supplies the physical footprint. And surrounding the BioHub at City Garage is an increasingly dense cluster — LaunchPort’s medtech acceleration platform, on-site cleanroom manufacturing, Workforce Genetics for talent, and three co-located venture firms in PTX Capital, Ecphora Capital, and Blackbird BioVentures.
Aletira is the first company to activate the entire loop at once. If the company executes on its seed-stage milestones over the next 18 to 24 months — advancing lead programs toward IND-enabling studies, raising a competitive Series A, retaining hiring in Baltimore — the next several spinouts from the Blackbird pipeline land in a demonstrably different ecosystem than the one that existed when Avidea was acquired four years ago.
What to Watch Next
The launch announcement is, appropriately, short on specifics. Lead indications, pipeline breadth, and the identity of lead and co-investors in the seed round have not yet been disclosed. Those details — along with the company’s initial hiring footprint and the timing of its next financing — will be the real measure of whether Aletira is the template for what comes next or an outlier.
Three signals will be worth tracking closely through the rest of 2026. First, whether the remaining three licensed Blackbird programs follow Aletira through the same full-stack path, and on what timeline — that is the test of whether the model is repeatable or whether the first spinout benefited from a particularly well-matched founder. Second, whether the seed-to-Series A arc for Aletira attracts top-tier coastal gene therapy investors into Baltimore rounds — the ultimate stress test of whether the city can host capital-intensive therapeutics companies without losing them. Third, whether second-time founders from other Baltimore exits — not just alumni of the Avidea–Barinthus lineage — begin to organize their next companies around the Blackbird platform. Density is the outcome that matters most, and it only becomes visible in the second and third cohorts.
For now, Aletira is exactly what the Blackbird thesis needed at the three-year mark: a concrete, named, fully incubated company with credentialed leadership, meaningful science, committed capital, and a desk at the BioHub. The next proof point is the second one.
ABOUT ALETIRA THERAPEUTICS
Aletira Therapeutics is a Baltimore-based gene therapy company developing cell-type-specific genetic medicines powered by an alternative splicing platform licensed from Johns Hopkins University. The company is the first fully incubated spinout of Blackbird Laboratories and is headquartered at the Blackbird BioHub at City Garage. More at aletiratherapeutics.com.
BioBuzz is an independent regional life sciences media and network platform connecting the BioHealth Capital Region, Philadelphia, and the Research Triangle. Coverage of the Blackbird BioHub launch is available at news.biobuzz.io.
